News Release Takeda Pharmaceutical Company Limited AstraZeneca K.K. Mitsubishi Tanabe Pharma Corporation Eisai Co., Ltd. Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori

Source URL: www.mt-pharma.co.jp

• Benzimidazoles
• Pyridines
• Sulfoxides
• Organic chemistry
• Gastroenterology
• Omeprazole
• Helicobacter pylori eradication protocols
• Rabeprazole
• Helicobacter pylori
• Medicine
• Proton pump inhibitors
• Chemistry

January 16, 2014 Press Release Mitsubishi Tanabe Pharma Corporation TELAVIC 250 mg Tablets, Antiviral Application for Additional Indication for Chronic Hepatitis C Genotype 2

Source URL: www.mt-pharma.co.jp

• Biology
• Medicine
• Pyrazines
• Telaprevir
• Cytokines
• Hepatitis C virus
• Hepatitis
• Interferon
• Hepatitis C
• Antivirals
• Pharmacology
• Protease inhibitors

April 23, 2014 Mitsubishi Tanabe Pharma Corporation Change of Representative Directors and Personnel Osaka, Japan, April 23, [removed]Mitsubishi Tanabe Pharma Corporation informally decided upon the following change of

Source URL: www.mt-pharma.co.jp

• Economy of Japan
• Business
• Chief executive officer
• Mitsubishi Pharma
• Director
• Executive officer
• Mitsubishi Motors
• Corporate governance
• Mitsubishi companies
• Management

April 3, 2013 Press Release Mitsubishi Tanabe Pharma Corporation Launch of BindRen® for Treatment of Hyperphosphatemia in Germany and Austria Osaka, Japan, April 3, 2013—Mitsubishi Tanabe Pharma Corporation (President

Source URL: www.mt-pharma.co.jp

• Kidney diseases
• Nephrology
• Phosphate binders
• Hyperparathyroidism
• Secondary hyperparathyroidism
• Dialysis
• Hyperphosphatemia
• Phosphorus
• Chronic kidney disease
• Medicine
• Chemistry
• Health

May 8, 2012 Mitsubishi Tanabe Pharma Corporation Notice of Dividend of Retained Earnings Osaka, Japan, May 8, [removed]Mitsubishi Tanabe Pharma Corporation (President & CEO:

Source URL: www.mt-pharma.co.jp

• Dividend
• Generally Accepted Accounting Principles
• Business
• Ex-dividend date
• Retained earnings
• Money
• Dividends
• Financial ratios
• Finance

June 14, 2013 Press release: Mitsubishi Tanabe Pharma Corporation Approval for Additional Indication for Atrial Fibrillation (Tachycardiac ) MAINTATE® Tablets: Selective β1 Blocker

Source URL: www.mt-pharma.co.jp

• Cardiology
• Chemistry
• Beta blockers
• Atrial fibrillation
• Bisoprolol
• Antiarrhythmic agents
• Systole
• Sotalol
• Cardiac dysrhythmia
• Alcohols
• Circulatory system

June 1, 2012 Press Release Mitsubishi Tanabe Pharma Corporation Termination of License Agreement with Cytochroma for MT[removed]Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism

Source URL: www.mt-pharma.co.jp

• Mitsubishi
• Hyperparathyroidism
• Mitsubishi Chemical Holdings
• Economy of Japan
• Mitsubishi companies
• Secondary hyperparathyroidism

June 30, 2014 Press release: Mitsubishi Tanabe Pharma Corporation Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS)

Source URL: www.mt-pharma.co.jp

April 1, 2013 PRESS RELEASE Mitsubishi Tanabe Pharma Corporation U.S. FDA Approves Canagliflozin (TA[removed]for the Treatment of Adult Patients with Type 2 Diabetes

Source URL: www.mt-pharma.co.jp

• Diabetes mellitus
• SLC5A2
• Anti-diabetic medication
• Diabetes
• Health
• Medicine

September 20, 2012 Press Release Mitsubishi Tanabe Pharma Corporation Launch of "Simponi®”, a human TNFα monoclonal antibody in Indonesia Osaka, Japan, September 20, [removed]Mitsubishi Tanabe Pharma Corporation (Pres

Source URL: www.mt-pharma.co.jp

• Arthritis
• Pharmacology
• Centocor
• Monoclonal antibodies
• Autoimmune diseases
• Golimumab
• Rheumatoid arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
• Medicine
• Health
• Rheumatology